medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2017, Number 5

<< Back Next >>

Rev Mex Urol 2017; 77 (5)

International Prostate Symptom Score and Gea Visual Analogue Scale ® comparison for evaluating lower urinary tract symptoms

Preciado-Estrella DA, Kaplan SA, Iturriaga-Goyón E, Ramón-Trejo E, Mayorga-Gómez E, Auza-Benavides A

Language: Spanish
References: 14
Page: 372-382
PDF size: 424.21 Kb.


ABSTRACT

Background: The World Health Organization approved the International Prostate Symptom Score (IPSS) in 1992 as an instrument for evaluating lower urinary tract symptoms in populations living in industrialized countries. However, there are populations for which the questionnaire is complicated, producing false results.
Objetive: To compare the IPSS with the Visual Analogue Scale (VAS-GEA) in patients with lower urinary tract symptoms.
Materials and Methods: An analytic, comparative, cross-sectional study was conducted at the Hospital General Dr. Manuel Gea González within the time frame of March and July 2016. Men above 45 years of age with lower urinary tract symptoms were evaluated through the IPSS and the VAS-GEA, the latter of which was developed together with specialists in Phoniatrics and Graphic Design. Both instruments were applied to each patient, registering the sociodemographic variables, accuracy, and response time. The 2 test was employed for the continuous variables and the Student’s t test for the distribution of means. The Wilcoxon test was used to compare the median of the two samples and determine their differences. The results were analyzed using the SPSS program (version 22.0, IBM).
Results: The study included 121 men with a mean age of 67 years and a mean educational level of 7 years. Thirty-five percent of the patients were unemployed and 8% spoke an indigenous language. Fifty-four patients (40%) asked for help in answering the IPSS due to visual or socio-intellectual limitations, whereas only 14 patients (11%) asked for help in answering the VAS-GEA, with 87% completing it (2:11.68, p ‹ 0.05). The mean time for completing the IPSS was 280 seconds, compared with 170 seconds for the VAS-GEA (Student’s t test: 19.64, p ‹ 0.05).
Conclusions: The VAS-GEA is proposed as an alternative to the IPSS for evaluating lower urinary tract symptoms in patients that have intellectual, linguistic, academic, or sensory limitations.


REFERENCES

  1. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549-57.

  2. Kaplan S, Goluboff E, Olsson C, Deverka P, Chmel Joseph. Effect of demographic factors, urinary peak flow rates, and Boyarsky. Symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology. 1995;45(3):298-405.

  3. Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology. 2000;55:540-546.

  4. MacDiarmid SA, Goodson TC, Holmes TM, Martin PR, Doyle RB. An assessment of the comprehension of the American Urological Association Symptom Index. J Urol. 1998;159:873-874.

  5. Afriansyah A, Gany YI, Nusali H. Comparison between visual prostate symptom score and international prostate symptom score in males older than 40 years in rural Indonesia. Prostate Int. 2014;2(4):176-81.

  6. Rodríguez-García JM. Análisis comparativo de confiabilidad y validez de dos escalas de anomia. R Interam Psychol. 2006;40(2):193-204.

  7. Van der Walt CL, Heyns CF, Groeneveld AE, Edlin RS, van Vuuren SP. Prospective comparison of a new visual prostate symptom score versus the international prostate symptom score in men with lower urinary tract symptoms. Urology. 2011;78:17-20.

  8. Heyns CF, van der Walt CL, Groeneveld AE. Correlation between a new visual prostate symptom score (VPSS) and uroflowmetry parameters in men with lower urinary tract symptoms. S Afr Med J. 2012;102:237-40.

  9. McVary K, Roehrborn C. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH), Appendix 6: The AUA Symptom Index. 2010: 277.

  10. Heyns CF, Steenkamp BA, Chiswo J, Stellmacher GA, Fortsch HE, Van der Merwe A. Evaluation of the visual prostate symptom score in a male population with great language diversity and limited education: a study from Namibia. S Afr Med J 2014;104:353-7.

  11. Johnson TV, Abbasi A, Ehrlich SS, et al. Patient misunderstanding of the individual questions of the American Urological Association Symptom Score. J Urol. 2008;179:2291- 2295.

  12. Netto NR, de Lima ML. The influence of patient education level on the International Prostatic Symptom Score. J Urol. 1995;154: 97-99.

  13. Barry MJ, Fowler JF, Chang Y, et al, The American Urological Association symptom index: Does mode of administration affect its psychometric properties? J Urol 1995;154:1056-9.

  14. Park YW, Lee JH. Correlation between the visual prostate symptom score and international prostate symptom score in patients with lower urinary tract symptoms. Int Neurourol J. 2014;18:37-41.




2020     |     www.medigraphic.com